gesunheitpfleges.org



Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

February 02, 2016

In addition to otelixizumab, Tolerx has four product candidates in various stages of development, and each candidate is based on Tolerx's immunology expertise in understanding how therapies can be designed to normalize the immune system. These other product candidates in Tolerx's pipeline are:

TRX518, an immunotherapy in Phase 1 development for cancer, targets and activates the glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX1, a nonlytic anti-CD4 antibody that has completed early stage clinical studies and is currently being evaluated for the treatment of undesirable or aberrant humoral (anti-body-related) immune responses.. TRX585 and TRX385, that enhance immune responses by targeting the immunoglobulin-like transcript (ILT) family of receptors, are being evaluated for the treatment of cancer and viral disease.

SOURCE Tolerx, Inc.